Journal List > Korean J Gastroenterol > v.56(1) > 1006759

Song: Is 24 Weeks of Peginterferon and Ribavirin Combination Therapy Sufficient for the Patients with Genotype 1 Chronic Hepatitis C?


1. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49:1335–1374.
2. Shin HR. Epidemiology of hepatitis C virus in Korea. Intervirology. 2006; 49:18–22.
3. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39:1147–1171.
4. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007; 357:2576–2588.
5. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005; 129:528–536.
6. Ferenci P, Brunner H, Laferl H, et al. A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology. 2008; 47:1816–1823.
7. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology. 2008; 47:1884–1893.
8. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006; 44:97–103.
9. Moon SS, Kang HG, Seo JA, et al. 24 weeks treatment with pegylated interferon alfa plus ribavirin may be possible in genotype 1 chronic hepatitis C patients with rapid virological response who have low pretreatment viremia. Korean J Gastroenterol. 2010; 56:33–38.
10. Jensen DM, Morgan TR, Marcellin P, et al. Early identi-fication of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006; 43:954–960.
11. Lee CM, Hung CH, Lu SN, Changchien CS. Hepatitis C virus genotypes: clinical relevance and therapeutic implications. Chang Gung Med J. 2008; 31:16–25.
12. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev. 2000; 13:223–235.
13. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med. 1996; 125:634–639.
14. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008; 135:451–458.

Table 1.
Summary of the Rate of Sustained Virological Response in Genotype 1 Chronic Hepatitis C Patients with Rapid Virological Response who Completed 24 or 48 Weeks of Therapy
Authors HCV RNA levels Sustained virological response (%)
24 weeks of therapy 48 weeks of therapy
Zeuzem et al.8. ≤600,000 IU/mL 89% 85%
Ferenci et al.14. ≤400,000IU/mL 81.3% Not available
400,000-800,000 IU/mL 80.6%
>800,000 IU/mL 66.7%
Yu et al.7. ≤400,000 IU/mL 96.4% 100%
>400,000 IU/mL 76.5% 100%
Moon et al.9 >600,000 IU/mL 100% 96.2%
Similar articles